Effect of Over-the-Counter Fish-Oil Administration on Plasma Lp(a) Levels in an End-Stage Renal Disease Population

Journal of Renal Nutrition

Volumn 19, Issue 6, 2009, Pages 443-449

  Beavers, Kristen M ^a   Beavers, Daniel P ^a   Bowden, Rodney G ^a   Wilson, Ronald L ^b   Gentile, Mindy ^c  

^a BAYLOR UNIVERSITY   (United States)

^b Central Texas Nephrology Associates   (United States)

^c Genzyne Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORN OIL; FISH OIL; LIPOPROTEIN A; NON PRESCRIPTION DRUG;

ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

CORN OIL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FISH OILS; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEIN(A); MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

ZEA MAYS;

EID: 70349962913     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2009.06.005     Document Type: Article

References (37)

1. Excerpts from the United States renal data system 1998 annual data report. Am J Kidney Dis 32 Suppl (1998) S1-S162
2. Longenecker J.C., Coresh J., Powe N.R., et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 13 (2002) 1918-1927
3. Shoji T., Kimoto E., Yamada A., et al. Elevated plasma free apo(a) levels in hemodialysis patients. Nephron 83 (2000) 389-390
4. Rhoads G.G., Dahlen G., Berg K., et al. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 256 (1986) 2540-2544
5. Bostom A.G., Gagnon D.R., Cupples L.A., et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 90 (1994) 1688-1695
6. Wild S.H., Fortmann S.P., and Marcovina S.M. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 17 (1997) 239-245
7. National Institutes of Health. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
8. Huby T., Schroder W., Doucet C., et al. Characterization of the N-terminal and C-terminal domains of human apolipoprotein(a): relevance to fibrin binding. Biochemistry 34 (1995) 7385-7393
9. Beisiegel U., Niendorf A., Wolf K., et al. Lipoprotein(a) in the arterial wall. Eur Heart J 11 (1990) 174-183
10. Dangas G., Mehran R., Harpel P.C., et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 32 (1998) 2035-2042
11. Nielsen L.B. Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis 143 (1999) 229-243
12. Miles L.A., and Plow E.F. Lp(a): an interloper into the fibrinolytic system?. Thromb Haemost 63 (1990) 331-335
13. Utermann G. The mysteries of lipoprotein(a). Science 246 (1989) 904-910
14. Carlson L.A., Hamsten A., and Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 226 (1989) 271-276
15. Marcovina S.M., Kennedy H., Bittolo Bon G., et al. Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania: the Lugalawa Study. Arterioscler Thromb Vasc Biol 19 (1999) 1250-1256
16. Nelson G.J., and Ackman R.G. Absorption and transport of fat in mammals with emphasis on n-3 polyunsaturated fatty acids. Lipids 23 (1988) 1005-1014
17. Herrmann W., Biermann J., and Kostner G.M. Comparison of effects of n-3 to n-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease. Am J Cardiol 76 (1995) 459-462
18. Haglund O., Mehta J.L., and Saldeen T. Effects of fish oil on some parameters of fibrinolysis and lipoprotein(a) in healthy subjects. Am J Cardiol 74 (1994) 189-192
19. Beil F.U., Terres W., Orgass M., et al. Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia. Atherosclerosis 90 (1991) 95-97
20. Eritsland J., Arnesen H., Berg K., et al. Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long-term n-3 fatty acid supplementation. Scand J Clin Lab Invest 55 (1995) 295-300
21. Svensson M., Schmidt E.B., Jorgensen K.A., et al. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrol Dial Transplant 23 (2008) 2918-2924
22. Jasti S., Siega-Riz A.M., Cogswell M.E., et al. Pill count adherence to prenatal multivitamin/mineral supplement use among low-income women. J Nutr 135 (2005) 1093-1101
23. Lee J.Y., Kusek J.W., Greene P.G., et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 9 (1996) 719-725
24. Grundt H., Nilsen D.W., Hetland O., et al. Clinical outcome and atherothrombogenic risk profile after prolonged wash-out following long-term treatment with high doses of n-3 PUFAs in patients with an acute myocardial infarction. Clin Nutr 23 (2004) 491-500
25. Wu W.H., Lu S.C., Wang T.F., et al. Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women. Eur J Clin Nutr 60 (2006) 386-392
26. Helland I.B., Saugstad O.D., Saarem K., et al. Supplementation of n-3 fatty acids during pregnancy and lactation reduces maternal plasma lipid levels and provides DHA to the infants. J Matern Fetal Neonatal Med 19 (2006) 397-406
27. Mostad I.L., Bjerve K.S., Lydersen S., et al. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes. Eur J Clin Nutr 62 (2008) 419-429
28. Harper C.R., and Jacobson T.A. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 51 (2008) 2375-2384
29. Rylance P.B., Gordge M.P., Saynor R., et al. Fish oil modifies lipids and reduces platelet aggregability in haemodialysis patients. Nephron 43 (1986) 196-202
30. Marcovina S.M., Albers J.J., Wijsman E., et al. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 37 (1996) 2569-2585
31. Barbagallo C.M., Averna M.R., Sparacino V., et al. Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron 64 (1993) 560-564
32. Willett W.C. The role of dietary n-6 fatty acids in the prevention of cardiovascular disease. J Cardiovasc Med 8 Suppl (2007) S42-S45
33. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J Ren Nutr 10 (2000) 191-195
34. Sandholzer C., Saha N., Kark J.D., et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 12 (1992) 1214-1226
35. Paultre F., Tuck C.H., Boden-Albala B., et al. Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population. Arterioscler Thromb Vasc Biol 22 (2002) 141-146
36. Longenecker J.C., Klag M.J., Marcovina S.M., et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: the CHOICE Study. Circulation 106 (2002) 2812-2818
37. Marcovina S.M., Gaur V.P., and Albers J.J. Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B. Clin Chem 40 (1994) 574-578